2023
P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Vieira D, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial. International Psychogeriatrics 2023, 35: 125-126. DOI: 10.1017/s1041610223002557.Peer-Reviewed Original ResearchPotential predictors of treatment outcomePredictors of treatment outcomeResponse to methylphenidateClinically significant apathyAlzheimer's Disease Cooperative Study ActivitiesMedium effect sizeMonths of methylphenidateAlzheimer's diseaseNPI-aMethylphenidate treatmentSignificant apathyApathetic patientsBaseline anxietyAD participantsMethylphenidatePotential predictorsActivities of Daily Living ScaleCompared to placeboNeuropsychiatric symptomsIndex scoreDaily Living ScaleAlzheimer's Disease Cooperative Study Activities of Daily Living ScaleApathyEffect sizeLiving ScaleHeterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg P, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Padala K, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. American Journal Of Geriatric Psychiatry 2023, 31: 1077-1087. PMID: 37385898, PMCID: PMC10765607, DOI: 10.1016/j.jagp.2023.06.002.Peer-Reviewed Original ResearchConceptsDiastolic blood pressureBlood pressureClinical predictorsDisease patientsAlzheimer's Disease Cooperative Study-ActivitiesHg diastolic blood pressureOptimal diastolic blood pressureMulti-center clinical trialDaily Living ScaleYears of ageAlzheimer's disease patientsHeterogeneity of responseApathy domainApathetic patientsClinical trialsFunctional impairmentTreatment benefitSignificant apathyLiving ScaleImpaired functionBaseline anxietyCholinesterase inhibitorsMedium effect sizeMethylphenidatePotential predictors
2022
Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Perin J, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.066932.Peer-Reviewed Original ResearchHeterogeneity of responseAlzheimer's diseaseAD patientsBaseline anxietyPlacebo-controlled clinical trialApathetic AD patientsDaily Living ScaleCommon neuropsychiatric symptomsLow functional capacityLower functional capabilityNPI apathy scoreLower baseline anxietyAD medicationsDifference of changesNeuropsychiatric InventoryNeuropsychiatric symptomsApathetic patientsClinical trialsMonth visitTreatment outcomesEffect differencesSignificant apathyLiving ScaleApathy scoresFunctional capacitySensory stimulation improves daily functions in Alzheimer’s disease
Cimenser A, Hempel E, Konisky A, Vaughan B, Megerian J, Malchano Z, Hajos M. Sensory stimulation improves daily functions in Alzheimer’s disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.060270.Peer-Reviewed Original ResearchADCS-ADLTreatment groupsFunctional abilityAlzheimer's diseaseSensory stimulationPlacebo groupAlzheimer's Disease Cooperative Study-ActivitiesDaily functional abilitiesAbnormal neuronal activityDaily Living ScalePlacebo group participantsGamma oscillationsGroup participantsSynchronized gamma oscillationsAbnormal neuronal functionHz gamma oscillationsTreatment group participantsClinical trialsDisease progressionPathological markersFunctional declineDifferent functional abilitiesLiving ScaleNeuronal activityDaily functionTracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
Tosin M, Simuni T, Stebbins G, Cedarbaum J. Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease? Journal Of Parkinson’s Disease 2022, 12: 1345-1351. PMID: 35466955, PMCID: PMC9198734, DOI: 10.3233/jpd-223170.Peer-Reviewed Original ResearchConceptsEmergent symptomsDisease progressionOutcome measuresParkinson's disease clinical trialsNon-motor symptomsEarly Parkinson's diseaseDaily Living ScalePatient-reported experiencesClinical rating scalesNovel outcome measuresSymptomatic treatmentPD progressionClinical trialsMedian numberDaily livingLiving ScaleParkinson's diseaseSummary scoresMDS-UPDRSUseful markerRating ScaleSTX groupProgressionStxSymptomsThe Effect of Dual Sensory Impairment and Multimorbidity Patterns on Functional Impairment: A Longitudinal Cohort of Middle-Aged and Older Adults in China
Wang Q, Zhang S, Wang Y, Zhao D, Chen X, Zhou C. The Effect of Dual Sensory Impairment and Multimorbidity Patterns on Functional Impairment: A Longitudinal Cohort of Middle-Aged and Older Adults in China. Frontiers In Aging Neuroscience 2022, 14: 807383. PMID: 35462686, PMCID: PMC9028763, DOI: 10.3389/fnagi.2022.807383.Peer-Reviewed Original ResearchDual sensory impairmentDaily Living ScaleMultimorbidity patternsFunctional impairmentSensory impairmentOlder adultsLiving ScaleCo-existing diseasesRetirement Longitudinal StudyMultimorbidity prevalenceFunctional statusLongitudinal cohortADL limitationsIADL limitationsInstrumental activitiesMultimorbidityRespiratory patternIntegrated careChina HealthImpairmentLongitudinal studyAdultsPrevalenceSelf-report measuresPotent pathway
2011
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77: 1253-1262. PMID: 21917766, PMCID: PMC3179648, DOI: 10.1212/wnl.0b013e3182309fa5.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4Dose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansInositolMagnetic Resonance ImagingMaleMental Status ScheduleMiddle AgedPeptide FragmentsPlatelet Aggregation InhibitorsTime FactorsTreatment OutcomeConceptsNeuropsychological test batteryAlzheimer's diseaseDose-ranging phase 2 studyAlzheimer's Disease Cooperative Study-ActivitiesClass II trialsClinical efficacy outcomesCSF biomarker resultsScyllo-inositol concentrationsPhase 2 studyPrimary efficacy analysisHigh-dose groupDaily Living ScaleBrain ventricular volumeCoprimary endpointsEarly discontinuationEfficacy outcomesII trialADCS-ADLDose groupEfficacy analysisAcceptable safetyAβx-42Living ScaleOptimal doseTreatment groups
2003
Predictors and clinical impact of epilepsy after subarachnoid hemorrhage
Claassen J, Peery S, Kreiter K, Hirsch L, Du E, Connolly E, Mayer S. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology 2003, 60: 208-214. PMID: 12552032, DOI: 10.1212/01.wnl.0000038906.71394.de.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAnxietyCausalityCerebral InfarctionComorbidityDisability EvaluationEpilepsyFemaleFollow-Up StudiesHematoma, SubduralHumansIncidenceMaleMiddle AgedNew YorkOdds RatioProspective StudiesQuality of LifeRecovery of FunctionRisk FactorsSickness Impact ProfileSubarachnoid HemorrhageConceptsModified Rankin ScaleSubarachnoid hemorrhageQuality of lifeCerebral infarctionFunctional recoverySubdural hematomaMore unprovoked seizuresPoor functional recoveryOutcome of epilepsyDaily Living ScaleNew-onset epilepsySickness Impact ProfileLawton Instrumental ActivitiesSpielberger Anxiety InventoryHospital dischargeRankin ScaleIndependent predictorsUnprovoked seizuresImpact ProfileClinical impactInstrumental activitiesLiving ScaleInstrumental disabilityFocal pathologyEpilepsy
2001
Relationship of cognitive ability to the developmental course of antisocial behavior in substance-dependent patients
Stevens M, Kaplan R, Bauer L. Relationship of cognitive ability to the developmental course of antisocial behavior in substance-dependent patients. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2001, 25: 1523-1536. PMID: 11642652, DOI: 10.1016/s0278-5846(01)00210-x.Peer-Reviewed Original ResearchConceptsChildhood conduct disorderSubstance-dependent patientsPatient groupAbstinent substance dependent patientsConduct disorderNon-drug usersLiving ScaleDiagnostic criteriaPatientsControl groupCocaine dependenceSubstance dependenceDevelopmental courseAge 15Antisocial behaviorSubject groupsASPDSignificant differencesScoresAdultsDual alcoholDisordersPresent studyDisorder behaviorsAdulthood
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply